Serious Adverse Drug Reactions to Pyrimethamine-Sulphadoxine, Pyrimethamine-Dapsone and to Amodiaquine in Britain
Open accessThe DOI matches its Crossref record.
Abstract
All reports of adverse reactions with pyrimethamine-sulphadoxine (Fansidar), pyrimethamine-dapsone (Maloprim), and amodiaquine spontaneously reported through the UK national post-marketing system were reviewed. Retrospective reporting rates of serious reactions associated with these drugs were analysed using prescription data from the Department of Health, derived from the Prescription Pricing Authority, and relevant pharmaceutical companies. Whilst interpretation of these data requires caution, they allowed comparison with reporting rates from other studies. The reported rate for all serious reactions to pyrimethamine-sulphadoxine was 1 : 2100 prescriptions, and for cutaneous reactions was 1 : 4900 prescriptions, with a fatality rate of 1 : 11 100. The reported rate for serious reactions to pyrimethamine-dapsone was 1 : 9100 prescriptions, and for blood dyscrasias was 1 : 20 000 prescriptions, with a fatality rate of 1 : 75 000. The reported rate of blood dyscrasias associated with amodiaquine was 1 : 2100 users with a fatality rate of 1 : 31 000. Serious hepatic disorders occurred in 1 : 11 1000 pyrimethamine-sulphadoxine prescriptions, 1 : 75 200 pyrimethamine-dapsone prescriptions, and in 1 : 15 650 amodiaquine users. 35% of cases received these drugs needlessly as they were not exposed to drug resistant strains of Plasmodium falciparum. Since few serious reactions have been reported to chloroquine plus proguanil, these data support guidelines which restrict the use of reviewed drugs for those at greatest risk of infection. Dosage data indicated that fatalities had taken higher doses and continued prophylaxis after onset of symptoms. Two thirds of serious reactions to the compound antimalarials were reported in females.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
World Health Organization (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90300-6 · Cited by 1,085
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Antimalarial Drug Toxicity: A Review
Taylor, W. R. J., & White, N. J. (2004) · Drug Safety · doi:10.2165/00002018-200427010-00003 · Cited by 482
Systematic review of amodiaquine treatment in uncomplicated malaria
Olliaro, P., Nevill, C., LeBras, J., Ringwald, P., Mussano, P., Garner, P., & Brasseur, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06217-4 · Cited by 283
Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States
Maldonado, Y. A., Read, J. S., & COMMITTEE ON INFECTIOUS DISEASES (2017) · Pediatrics · doi:10.1542/peds.2016-3860 · Cited by 270
Peters, P. J., Thigpen, M. C., Parise, M. E., & Newman, R. D. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00003 · Cited by 174
Tagbor, H., Bruce, J., Browne, E., Randal, A., Greenwood, B., & Chandramohan, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69559-7 · Cited by 81
Metadata
- Authors
- Phillips-Howard, P. A., & West, L. J.
- Venue
- Journal of the Royal Society of Medicine
- Publisher
- SAGE Publications
- Published
- 1990-02
- Volume
- 83
- Issue
- 2
- Pages
- 82-85
- ISSN
- 0141-0768 (ISSN-L)
- 1758-1095
- OpenAlex
- W1916706013
- Cited by
- 117
- References
- 0
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.